Search our news archive and pharma companies…
|
Today's News | Note: News feeds may no longer be available for the articles on this page.
FDA
grants Salix drug rifaximin priority review 9:01 AM 8/25/2009
Bizjournals.com
Salix Pharmaceuticals' drug rifaximin has been granted priority for
review by the US FDA for hepatic encephalopathy (HE) a neurological disorder tied to liver failure. Salix sells
rifaximin as a treatment for travelers’ diarrhea as Xifaxan.
...
Protalix's
Gaucher drug wins fast-track review 8:20 AM 8/25/2009
Reuters
Protalix BioTherapeutics Inc said the US FDA will review its experimental treatment prGCD
for Gaucher disease on a fast-track basis. prGCD would compete with Genzyme Corp's Cerezyme.
...
GenVec
wins $2.5M grant 7:59 AM 8/25/2009
Bizjournals.com
GenVec Inc won more funding from the National Institutes of Health to support the
development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and
encoding inhibitory antigens.
...
Asia
way short of vaccine to fight swine flu-WHO 6:46 AM 8/25/2009
Reuters
The World Health Organization said Asia is not going to have enough new H1N1
vaccine to fight swine flu when the next surge of infections hits during the cold season.
...
FDA
OKs Sanofi allergy drug for younger children 4:09 PM 8/24/2009
Forbes
Sanofi-Aventis and drugmaker UCB said their once-daily allergy medication Xyzal
(levocetirizine) has received expanded US approval for children as young as six months.
...
CytRx
rises on preclinical data for stroke drug 1:15 PM 8/24/2009P
Forbes
CytRx Corp reported positive results from animal tests of its stroke recovery
drug candidate arimoclomol.
...
Ariad
rises on rehearing for drug patent case 9:26 AM 8/24/2009
Boston Globe
Ariad Pharmaceuticals said a federal court agreed to reconsider whether drugmaker
Eli Lilly infringed drug patents that cover any medical treatment targeting the body's molecular NF-kappa B
pathway. Eli Lilly drugs at issue include Evista and sepsis treatment Xigris.
...
Neurogen
acquired by Ligand Pharmaceuticals 8:19 AM 8/24/2009
Mass High Tech
Neurogen Corp entered a merger agreement to be sold to Ligand Pharmaceuticals Inc.
Ligand gains access to Neurogen’s existing partnership with Merck for vanilloid receptor subtype 1 (VR1)
antagonists, and H3 antagonist and oral erythropoietin (EPO) research programs.
...
Valeant's
pain drug fails in mid-stage trial, shrs fall 7:40 AM 8/24/2009
Reuters
Valeant Pharmaceuticals International said preliminary results showed its
experimental drug retigabine for the treatment of pain associated with shingles failed to meet the main goal of a
trial.
...
Cell
Therapeutics says FDA accepts NDA for cancer drug 6:30 AM 8/24/2009
Reuters
Cell Therapeutics said the US FDA has designated a standard review for
pixantrone as a treatment for relapsed aggressive non-Hodgkin's lymphoma.
...
Biovail,
Santhera strike Parkinson's drug deal 5:42 AM 8/24/2009
Reuters
Biovail struck a deal with Swiss biotech Santhera over JP-1730/fipamezole to treat
dyskinesia in Parkinson's disease.
...
Warner
Chilcott Is Set to Buy P&G's Prescription Drug
Unit 2:48 PM 8/23/2009
Wall Street
Journal
Warner Chilcott Ltd is expected to announce the acquisition of Procter & Gamble's
prescription-drug business for about $3 billion. Six banks are expected to put up the money to finance the
transaction.
...
Swine
Flu Campaign Waits on Vaccine 5:45 AM 8/23/2009
Washington Post
This campaign is haunted by the government's ill-fated 1976 effort to vaccinate
against swine flu. Forty million people were vaccinated as the epidemic fizzled. The vaccine blamed for causing a
rare paralyzing disorder known as Guillain-Barré Syndrome.
...
Johnson
& Johnson Epilepsy Drug Doesn't Win Clearance 5:21 PM 8/21/2009
Bloomberg
Johnson & Johnson said its experimental anti-epilepsy drug Comfyde
(carisbamate) failed to gain US FDA approval.
...
US
FDA OKs Lundbeck seizure drug for adults, infants 12:44 PM 8/21/2009
Reuters
H Lundbeck won US approval for Sabril for treating infantile spasms in
children ages one month to two years and adult use in combination with other medications to treat complex partial
seizures.
...
<- Day Earlier | Today's News
|
